STON1 Oral Solution (Potassium citrate + Magnesium citrate)
Table of Content
The lifetime prevalence of urolithiasis is estimated to be 1% to 15%, varying according to age, gender, race and geographic location. The calcium stones are the most common type of the stones and calcium oxalate stones accounts for 60% of all stone types. After the initial management of first stone episode, there is risk of recurrent stone formation due to underlying metabolic abnormalities. Recurrence rate is about 10% in one year, 35% in five years and 50% in ten years.
The common metabolic abnormalities are hypocitraturia, hyperoxaluria, hypercalciuria etc. Potassium magnesium citrate increases urinary citrate, urinary magnesium and urinary pH. In potassium magnesium citrate, magnesium and citrate act as inhibitors of stone formation. Potassium magnesium citrate therapy has been shown to reduce the recurrence rate of calcium oxalate stone formation by 85% in 3 years. Addition of pyridoxine to potassium magnesium citrate is beneficial as pyridoxine acts as a cofactor for the enzyme alanine-glyoxylate-transaminase which converts glyoxylate to glycine and makes less glyoxylate available for its conversion into oxalate. Thus it reduces the urinary oxalate excretion.
The recommended dosage for STON1B6 oral solution (potassium citrate, magnesium citrate plus pyridoxine hydrochloride) is three teaspoons (15ml) diluted with one glass of water, after meals twice daily. The dosage for STON1B6 tablets (potassium magnesium citrate plus pyridoxine hydrochloride) is two tablets,after meals thrice daily.